These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38094162)

  • 1. A novel transcranial photobiomodulation device to address motor signs of Parkinson's disease: a parallel randomised feasibility study.
    Herkes G; McGee C; Liebert A; Bicknell B; Isaac V; Kiat H; McLachlan CS
    EClinicalMedicine; 2023 Dec; 66():102338. PubMed ID: 38094162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Placebo-Controlled Study of a Transcranial Photobiomodulation Helmet in Parkinson's Disease: Post-Hoc Analysis of Motor Outcomes.
    McGee C; Liebert A; Bicknell B; Pang V; Isaac V; McLachlan CS; Kiat H; Herkes G
    J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson's disease.
    McGee C; Liebert A; Herkes G; Bicknell B; Pang V; McLachlan CS; Kiat H
    Front Neurosci; 2022; 16():945796. PubMed ID: 36061601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 receptor agonists for Parkinson's disease.
    Mulvaney CA; Duarte GS; Handley J; Evans DJ; Menon S; Wyse R; Emsley HC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012990. PubMed ID: 32700772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
    van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
    Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.
    Vitek JL; Jain R; Chen L; Tröster AI; Schrock LE; House PA; Giroux ML; Hebb AO; Farris SM; Whiting DM; Leichliter TA; Ostrem JL; San Luciano M; Galifianakis N; Verhagen Metman L; Sani S; Karl JA; Siddiqui MS; Tatter SB; Ul Haq I; Machado AG; Gostkowski M; Tagliati M; Mamelak AN; Okun MS; Foote KD; Moguel-Cobos G; Ponce FA; Pahwa R; Nazzaro JM; Buetefisch CM; Gross RE; Luca CC; Jagid JR; Revuelta GJ; Takacs I; Pourfar MH; Mogilner AY; Duker AP; Mandybur GT; Rosenow JM; Cooper SE; Park MC; Khandhar SM; Sedrak M; Phibbs FT; Pilitsis JG; Uitti RJ; Starr PA
    Lancet Neurol; 2020 Jun; 19(6):491-501. PubMed ID: 32470421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Giladi N; Alcalay RN; Cutter G; Gasser T; Gurevich T; Höglinger GU; Marek K; Pacchetti C; Schapira AHV; Scherzer CR; Simuni T; Minini P; Sardi SP; Peterschmitt MJ
    Lancet Neurol; 2023 Aug; 22(8):661-671. PubMed ID: 37479372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.
    LeWitt PA; Rezai AR; Leehey MA; Ojemann SG; Flaherty AW; Eskandar EN; Kostyk SK; Thomas K; Sarkar A; Siddiqui MS; Tatter SB; Schwalb JM; Poston KL; Henderson JM; Kurlan RM; Richard IH; Van Meter L; Sapan CV; During MJ; Kaplitt MG; Feigin A
    Lancet Neurol; 2011 Apr; 10(4):309-19. PubMed ID: 21419704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent theta-burst stimulation combined with physical therapy as an optimal rehabilitation in Parkinson's disease: study protocol for a randomised, double-blind, controlled trial.
    Jin ZH; Wang YX; Meng DT; Qin Y; Duan YN; Fang JP; Wang RD; Liu YJ; Liu C; Wang P; Yan HJ; Zhen Y; An X; Chen KK; Yu X; Lyu D; Yan XY; Fang BY
    Trials; 2023 Jun; 24(1):410. PubMed ID: 37328845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
    BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electroacupuncture for motor dysfunction and constipation in patients with Parkinson's disease: a randomised controlled multi-centre trial.
    Li K; Xu S; Wang R; Zou X; Liu H; Fan C; Li J; Li G; Wu Y; Ma X; Chen Y; Hu C; Liu X; Yuan C; Ye Q; Dai M; Wu L; Wang Z; Wu H
    EClinicalMedicine; 2023 Feb; 56():101814. PubMed ID: 36691434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson's Disease.
    Martínez-Fernández R; Máñez-Miró JU; Rodríguez-Rojas R; Del Álamo M; Shah BB; Hernández-Fernández F; Pineda-Pardo JA; Monje MHG; Fernández-Rodríguez B; Sperling SA; Mata-Marín D; Guida P; Alonso-Frech F; Obeso I; Gasca-Salas C; Vela-Desojo L; Elias WJ; Obeso JA
    N Engl J Med; 2020 Dec; 383(26):2501-2513. PubMed ID: 33369354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study.
    Gu SC; Ye Q; Wang CD; Zhao SR; Zhou J; Gao C; Zhang Y; Liu ZG; Yuan CX
    Front Pharmacol; 2022; 13():739194. PubMed ID: 35281890
    [No Abstract]   [Full Text] [Related]  

  • 18. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
    Front Neurol; 2021; 12():705407. PubMed ID: 34659081
    [No Abstract]   [Full Text] [Related]  

  • 19. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.